Epilepticus Status
Conditions
Brief summary
•Background: Intravenous clonazepam is the most widely used first-line benzodiazepine in Europe for the initial management of status epilepticus in children. The guidelines of the Société de reanimation de langue francaise (SRLF) and the société française de médecine d'urgence (SFMU) published in 2018 recommend an initial loading dose of 0.015 mg / kg of clonazepam in this situation (maximum 1.5 mg). To our knowledge, there is no specific study of the efficacy of clonazepam according to the dose used. Objective: To compare the effectiveness of the initial loading dose of clonazepam in children treated for status epilepticus •Methods: Monocentric retrospective study including children \< 16 years who have benefited from an initial loading dose of clonazepam in the context of status epilepticus treated at the Montpellier University Hospital between January 2016 and June 2019. The investigators collected data from medical records (clinic, treatment , evolution) and compared these according to the dosage of clonazepam used. •Discussion: Among the benzodiazepines used in the first-line treatment of pediatric status epileptic, lorazepam and midazolam are the most widely used drugs in the world. Lorazepam is not so much used in Europe because the injectable form is not available for a daily use. Conversely, clonazepam is used in a large number of European countries but is rarely used in the United States due to the lack of an injectable form. About the tolerance of treatment, except overdose situations, clonazepam is a drug well tolerated in the pediatric populatin. The main side effects of clonazepam are respiratory depression and impaired alertness. To our knowledge, this study is the first to examine the efficacy depending on the initial loading dosage of clonazepam in children status epilepticus.
Interventions
OTHEREfficacy of intravenous clonazepam
Efficacy of intravenous clonazepam
Sponsors
University Hospital, Montpellier
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
No minimum to 16 Years
Healthy volunteers
No
Inclusion criteria
An individual must fulfill all of the following criteria in order to be eligible for study enrollment: * Aged under 16 years * Status epilepticus taken care of at the CHU de Montpellier
Exclusion criteria
● No loading dose of clonazepam
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| effectiveness in stopping seizures | 1 day | The primary endpoint was clinical cessation of seizures, which was defined as the absence of clinical signs of seizures immediately following the injection of clonazepam. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| duration of seizure | 1 day | duration of seizure (minutes) |
| type of seizures | 1 day | type of seizures (focal, generalized); |
| aetiologies ; | 1 day | aetiologies (idiopathic, symptomatic) |
| pre-hospital treatment used | 1 day | pre-hospital treatment used |
| whether or not to use a dose greater than one milligram | 1 day | whether or not to use a dose greater than one milligram |
| need for a second dose of clonazepam | 1 day | need for a second dose of clonazepam |
| using another antiepileptic drug | 1 day | using another antiepileptic drug (phenobarbital, fosphenytoin, thiopental) |
| Hospitalization in an intensive care or resuscitation unit | 1 day | Hospitalization in an intensive care or resuscitation unit |
| Rate of hospitalization in conventional sector | 1 day | Rate of hospitalization in conventional sector |
| introduction of antiepileptic treatment after treatment | 1 day | introduction of antiepileptic treatment after treatment |
| introduction of a maintenance dose | 1 day | introduction of a maintenance dose |
Countries
France
Outcome results
None listed